

➤ **A collective
dynamic**
in the fight
against cancer

CENTRE
DE LUTTE
CONTRE LE CANCER
**LEON
BERARD**

**ACTIVITY
REPORT
2025**

All of these measures are there for one purpose: to provide every patient with personalised care at every stage of their illness, as quickly as possible, regardless of where they live.



P. 6

Key elements of the Centre Léon Bérard in 2025

- 7. Management structure and organization
- 8. Management structure
- 9. Medical departments
- 10. Technical platforms
- 12. The Centre Léon Bérard in 2025
- 12. Patient satisfaction
- 14. Highlights of 2025



P. 20

Care and support for each patient

- 21. 1. Prevention and screening
- 22. 2. Diagnosis
- 24. 3. Treatments
- 27. 4. Types of hospitalization and organization

- 30. 5. Supportive and complementary care



P. 60

Statement of sources and uses of income

P. 34

Innovation for all

- 35. 6. Clinical research
- 38. 7. Translational research
- 40. 8. Fundamental research



P. 42

Joining forces against cancer

- 43. 9. Education and training
- 46. 10. Social and environmental policy
- 48. 11. National and international partnerships
- 50. 12. Communication
- 51. 13. Fundraising

➤ Healthcare professionals and patients: meeting the challenge of cancer together

2025 marked the completion of the institution's plan for 2021-2025. Among the major strategic initiatives finalised this year, the opening of the **Christophe and Rodolphe Mérieux auditorium** marks an important milestone. Designed as a space that encourages conversation and collaboration among the site's doctors and researchers, it aims to accelerate research and innovation in the fight against cancer.

« This pivotal year has also been devoted to developing our new strategic project, structured around an ambitious 2026–2030 plan for the institution. »

In December, we also inaugurated the **Thierry Philip Prevention Centre**, the signature project of the CLB's 2021-2025 plan. This new building brings together a complete range of consultation solutions for cancer screening and prevention under one roof. The entrance, at 9 Boulevard Jean XXIII, gives it better visibility, meeting the public's needs in a tangible way. The centre also serves as a research facility, dedicated to gaining a better understanding of the causes of cancer and taking proactive measures. Plus, it provides a hub for expertise and resources for both healthcare professionals and the general public.

Most initiatives included in the 2021–2025 plan have been successfully completed. Some will be continued or incorporated into the next strategic cycle, if we can corroborate their relevancy. Because oncology is, in fact, constantly evolving:

new therapies and treatment strategies are emerging all the time, innovative equipment is being rolled out, and the growing integration of digital technology and artificial intelligence are transforming our practices and organisational structures in a profound way. In such a climate, agility and constant reassessment are essential.

This pivotal year has also been devoted to developing our new strategic project, structured around an ambitious 2026–2030 plan for the institution. Teams across all departments and directorates have identified priorities to be implemented for each type of tumour over the next five years in order to meet the needs of Auvergne-Rhône-Alpes. This policy factors in the evolution in prevalence of cancers as well as the reduced access to treatment given the declining numbers of healthcare professionals. **Eight main strategic priorities have therefore been identified:** "Optimising Clinical Management



and Care Pathways", "Innovation, Technologies and Theranostics", "Research, Clinical Trials and Real-world Data", "Training, Knowledge Transfer and Human Resource Development", "Strategic Partnerships and Collaborations", "Prevention and Screening" and "Environmental Impact and Collective Commitment".

Over the next five years, the institution will also move forward on its major structural projects, especially **the extensions for buildings** such as CLB 2 and CLB 3. We are also planning on **purchasing cutting-edge equipment**, such as a photon-counting scanner. The aim is to use it for research purposes initially, and then to allow its clinical use to benefit patients in the region.

All of these measures are there for one purpose: **to provide every patient with personalised care at every stage of their illness, as quickly as possible, regardless of where they live.** This is what makes the network of cancer treatment centres so key; located throughout the country,

« Provide every patient with personalised care at every stage of their illness, as quickly as possible, regardless of where they live. »

they focus exclusively on oncology care, guaranteeing a public service and ensuring that patients don't face any additional fees for the treatment they receive.

editorial



Prof Jean-Yves Blay
Executive Director
of the Centre Léon Bérard



Key elements of the Centre Léon Bérard in 2025



› Governance and organisation

Makeup of the Executive Board as of 31 December 2025

Members with voting rights

› President

Fabienne BUCCIO (January 11, 2023)
Prefect of the Auvergne-Rhône-Alpes region, Prefect of the Rhône

› Representative of the Medical Training and Research Unit (UFR) Claude Bernard Lyon 1 University

Prof Carole BURILLON (January 2021) President of the Medical Studies Coordinating Committee in Lyon

› Representative of the Hospices Civils de Lyon

Raymond LE MOIGN (October 2020)
Executive Director of the Hospices Civils de Lyon

› Representative of the National Cancer Institute (INCa)

Prof Alain Viari (renewed by INCa in October 2024)
National Institute for Research in Digital Science and Technology (Inria), Grenoble Rhône-Alpes

› Representative of the Regional Economic and Social Council

Anne-Marie ROBERT (May 2024)

› External expert members (March 2023-March 2026)

Laurence FAUTRA (September 2022 / term renewed in March 2023)
Vice-President of the Auvergne-Rhône-Alpes Regional Council
Anne BRUGNERA (January 2020 / term renewed in March 2023)

Prof Frédérique PENAULT-LLORCA (March 2023)

Managing Director of the Jean-Perrin, Clermont-Ferrand Comprehensive Cancer Centre

Pierre BIRON (February 2023, term renewed in March 2023)
Former Head of the Department of Medicine and former Director of Medical Affairs at CLB

› User Representatives (March 2023 - March 2026)

Jeanine LESAGE (November 2020 / term renewed in March 2023)
Vice-President of the National League Against Cancer, Rhône Committee
Jean Pierre MARTIN (December 2021, term renewed in March 2023)
President of the National League Against Cancer, Rhône Committee

› Representatives of the CLB Medical Association Committee

Dr Pierre-Eric ROUX (December 2022)

Dr Virginie AVRILLON (December 2022)

› Representatives of the Social and Economic Committee

Martine Maritan BERUZON (November 2022)

Mélanie LABBÉ (November 2022)

Members with advisory status

› Director of the Auvergne-Rhône-Alpes Regional Health Authority (ARS-ARA)

Cécile COURREGES (May 2023)

Represented by **Philippe GUETAT**

› Delegate General for Unicancer

Sophie BEAUPÈRE (October 2021)

› Executive Director of the Centre Léon Bérard

Prof Jean-Yves BLAY


› Centre Léon Bérard employees

Damien SEBILEAU, Deputy Executive Director
Anne-Sophie NICOLOSO, Director of Human Resources
Sandrine MOUNIER, Director of Finance and Administration
Patrick MELHEN, Director of Basic/Translational Research and the Cancer Research Centre of Lyon (CRCL)
Anne MIERMONT, General Secretary

› Auditor

Valérie MALNOY

› Organisational chart



Medical departments

› The bodies

Executive Board
Fabienne Buccio

Social and Economic Committee
Martine Maritan Beruzon

Scientific Advisory Board
Prof Eric Solary

Users' Commission
Dr Amine Belhabri

COVIRISQ (risk management committee)
Dr Helen Boyle

› Medical Departments

› MEDICAL DEPARTMENTS DEPARTMENT OF PATHOBIOLOGY

Dr Marie Karanian

› DEPARTMENT OF ANAESTHESIOLOGY

Dr Sabine De Lamer

› DEPARTMENT OF SURGERY

Dr Pierre Meeus

› DEPARTMENT OF MEDICAL ONCOLOGY

Dr Olivier Trédan

Dr Thomas Bachelot
Co-head of the Department of Medical Oncology

Dr Anne-Sophie Michallet
Co-head in charge of haematological tumours

› DEPARTMENT OF RADIOTHERAPY

Dr Anne-Agathe Serre

› DEPARTMENT OF NUCLEAR MEDICINE LUMEN CENTRE

Dr Thomas Mognetti

› DEPARTMENT OF SUPPORTIVE CARE OF ONCOLOGY PATIENTS

Prof Gisèle Chvetzoff

› DEPARTMENT OF RADIOLOGY

Prof Frank Pilleul

› DEPARTMENT OF OUTPATIENT CARE AND INTERFACE CO-ORDINATION

(at home hospitalisation and care)

Dr Bruno Russias

› DEPARTMENT OF PHARMACY

Dr Bertrand Favier
Managing Pharmacist

› DEPARTMENT OF MEDICAL PHYSICS

Dr Marie-Claude Biston

› DEPARTMENT OF PAEDIATRIC ONCOLOGY

Institute of Paediatric Haematology and Oncology (IHOPE):
Dr Perrine Marec-Bérard

› DEPARTMENT OF PREVENTION AND PUBLIC HEALTH

Prof Christine Lasset

› DEPARTMENT OF CANCER PREVENTION AND THE ENVIRONMENT

Prof Béatrice Fervers

> Technical facilities



01

> 3 OPERATING BLOCKS

3 operating blocks comprising 19 theatres:

- > 1 block with 11 theatres
- > 1 block specifically for screening endoscopies, interventional radiology and the vascular access unit for establishing venous ports
- > 1 brachytherapy block
- > 2 post-operative recovery rooms

02

> THE RADIOTHERAPY CENTRE

One of the largest radiotherapy centres in France with 8 accelerators - 1 Cyberknife®, 2 tomotherapy machines and 5 Elekta accelerators - on 2 sites in Lyon and Villefranche-sur-Saône. Together with the Hôpital Nord-Ouest, and a brachytherapy block, the centre forms a cooperative healthcare consortium with expertise in paediatric radiotherapy.

03

> IMAGING

An imaging unit equipped with two MRI scanners, two CT scanners, X-ray machines, ultrasound scanners, two mammography units – one of which is reserved for stereotactic-guided biopsies – and a women's health centre.

04

> PATHOBIOLOGY

A biopathology unit combining pathological anatomy and cytology with molecular biology.

05

> NUCLEAR MEDICINE

A nuclear medicine unit equipped with two fully digital PET scanners and 3 gamma cameras, 1 of which is a Veriton-CT, as part of the LUMEN Centre, forming a cooperative healthcare consortium with the Hospices Civils de Lyon and the Centre Léon Bérard.

The Centre Léon Bérard in 2025

Healthcare and research

44,008
patients treated
(+1%) including **11,317**
new patients (-5%)

345
beds and places
on surgical and
medical wards

214
hospitalisation
at home places

119,042
consultations
and **11,125** video
consultations

11,265
conventional
admissions

43,528
outpatient medical
admissions
(excluding the Unplanned
Admissions Management
Unit – UAMU)

6,577
outpatient surgical
admissions


2 668
patients included
in clinical trials (all
types of trials), i.e. **19.1%**
of the active list

325
scientific
publications


Data as of 31 December 2025

CLB staff

› **2,424** employees



› **36** professions
in the following
sectors:




The profile of CLB patients

(data from the complete active list)


› **44,008**
patients



How old are they?



Where are they from?




Focus on IHOPe*

(based on data for
hospital stays)

* Paediatric Haematology and
Oncology Institute, a Cooperative
Healthcare Consortium of the
Hospices Civils de Lyon and the
Centre Léon Bérard



106
IHOPe
CLB



110
IHOPe
HCL

Patient satisfaction

In 2025, the Haute Autorité de Santé (national health authority) published the results of a patient satisfaction survey following their hospital stays. The 2025 e-satis survey covered some 940 healthcare facilities for admissions of more than 48 hours and 861 facilities for outpatient surgery. Satisfaction scores out of 100 were compiled from the patients' responses and for 2025, the Centre Léon Bérard obtained a score of 81/100 for stays of at least 48 hours and 83.6/100 for outpatient surgery.

The CLB is therefore among the **29.7% of healthcare facilities in France (279 facilities)** to obtain the grade **A** for stays of more than 48 hours and among the **64.5% of facilities graded A (563 facilities)** for outpatient surgery.

83 %
of patients admitted
would recommend
our facility

85.8 %
of outpatient
surgery patients
would recommend
our facility

Score out of 100

Overall score from patients admitted	81 - A
Reception	86.6
Provision of care	
Care by doctors/surgeons	88
Care by nurses/nursing assistants	86.6
Meals	68.7
Rooms	78.6
Organisation of discharge	71.7

Response rate: 29.9% (1,008 replies out of 3,373 emails sent)

Score out of 100

Overall score from surgical outpatients	83.6 - A
Pre-admission satisfaction	86.8
Satisfaction with reception on the day of surgery	88.4
Provision of care	88.8
Room and meal	76.8
Organisation of discharge and return home	77.4

Response rate: 30.5% (1,637 replies out of 5,376 emails sent)

Highlights of 2025



APRIL

► Epione® : the robot that can destroy abdominal and pulmonary tumours

The Centre Léon Bérard (CLB) has installed Epione®, the Quantum Surgical platform that enables early and curative treatment of tumours. This makes CLB the sixth site in France to offer this minimally invasive treatment, which is able to destroy abdominal and pulmonary tumours by inserting a needle through the skin.

The Epione® robotic platform developed by Quantum Surgical enables surgeons to perform safe and effective percutaneous tumour ablations. This minimally invasive treatment is an alternative to surgery. It involves inserting one or more needles through the skin to access the tumour and destroy it. Some 875 patients around the world have already been treated thanks to Epione®, and now it is also available at the Centre Léon Bérard.

"The adoption of the Epione robot marks a major advancement for our department and our patients. Thanks to this cutting-edge technology, we can perform minimally invasive procedures with unmatched precision, thereby reducing risks and significantly improving patient care. This innovation strengthens our commitment to providing the highest quality of care in interventional radiology," explains Dr Amine Bouhamama, interventional radiologist at the CLB. ●



MAY

► France's first Grey May

The Centre Léon Bérard partnered with the "Grey May" initiative that started in Canada. The aim of the month is to raise awareness and educate the general public about brain tumours, as well as supporting research and patients suffering from this cancer. The event was organised for the first time in France in Lyon, at the instigation of CLB doctors treating rare pathologies. Two information days were organised: one aimed at adults, and the other for adolescents and young adults (AYA). The programme included workshops to help better understand and prepare for lumbar punctures and the wearing of radiotherapy immobilisation masks, as well as a session on "caring for your scalp" with a specialist hairdresser. Activities focused on adapted physical activity or on exploring the anatomy using an "inflatable brain" were also offered. Members of the CLB's support pathway and the social services department took part in the day's events too.

And workshops were also organised by these patients' associations: Plus cérébrale que nous tumeur, LFS France, Des étoiles dans la mer - Vaincre le glioblastome and onCOGITE.

Two conferences were held: one for adult patients, "Brain tumours and metastases: current treatments, therapeutic innovations and supportive care", and one for AYAs, "Building Futures: how getting back to work works and how to support those who support others".

And then there was a medical-scientific day to review the latest advances. ●

SaGoVie
QUALITÉ DE VIE

Cancer du sein
TRIPLE NÉGATIF
métastatique

Vous suivez un traitement par
Sacituzumab Govitecan (TRODELVY) ?
Partagez votre expérience et votre vécu !

UNE ÉTUDE NATIONALE
SaGoVie est une étude co-construite par le Collectif Tripletttes Roses et le Centre Léon Bérard à Lyon. Elle vise à évaluer différemment la qualité de vie des patientes atteintes de cancer du sein triple négatif métastatique, sous Sacituzumab-Govitecan (après plus de trois mois). Nous avons besoin de vous pour identifier les difficultés spécifiques rencontrées selon la durée du traitement et évaluer votre perception de la prise en charge de ses symptômes. Nous pourrions ainsi déterminer les besoins prioritaires des patientes sous Sacituzumab-Govitecan.

TÉMOIGNAGE
"Je suis sous Trodelvy depuis plus de deux ans. Je suis en vie mais ma qualité de vie s'est dégradée au fil des mois. Cette étude est cruciale pour faire entendre la voix des tripletttes et bénéficier de soins de support adaptés."
Vanessa Chardonnet Hecce
Vice-Présidente
Collectif Tripletttes Roses

Nous recherchons 40 à 80 témoignages au niveau national pour comprendre et améliorer le vécu des patientes sous Trodelvy. (Les entretiens seront réalisés à distance).


Et si le vôtre en faisait partie ?
Contactez-nous
Par e-mail : sagovie@lyon.univcancer.fr

JUNE

Tripletttes X LEON BERARD

► SaGoVie: patients and researchers set up a quality of life study together

The Collectif Tripletttes Roses association and the Centre Léon Bérard have launched a different kind of study to assess the quality of life of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan. Since it became available in France in late 2021, sacituzumab govitecan, an antibody-drug conjugate (ADC) from the United States, has had a big impact on metastatic triple-negative breast cancer treatment, doubling the life expectancy of affected patients. However, cumulative side effects affect patients' quality of life and impact their daily lives. These have not been sufficiently studied as yet. SaGoVie is a nationwide, multi-centre, participatory study for which the Centre Léon Bérard will interview approximately 60 patients during a remote session lasting a maximum of one hour. The aim is to identify the specific difficulties encountered depending on the length of treatment and to assess patients' perceptions regarding the management of these symptoms. This will make it possible to assess their primary needs in terms of supportive care. ●




SEPT.

► La Scintillante: sponsored walks and runs against cancer, back for a sixth time!

A new record was set during this sixth edition of a sponsored walk and run organised by the Centre Léon Bérard. Two alternatives were on the programme, neither timed, giving participants a chance to explore Lyon while fighting cancer. More than €400,000 were donated thanks to the 6,000 participants - a new record!

La Scintillante is a charity sports event organised entirely by the Centre Léon Bérard. Created in 2020, its goal is to raise funds for cancer research. For the sixth edition, La Scintillante 2025 was held in Lyon, at the Parc de la Tête d'Or (6th arrondissement), on Sunday 28 September. As with previous years, participants came together for a 5K urban walk or a 9K run (speed walking was also permitted). Everyone set their own pace and covered their chosen distance in what was a real moment of togetherness, based on solidarity and hope. Since it began, the event has raised more than €1.6 million in donations, all going towards the cancer research carried out at the Centre Léon Bérard. ●



OCT.

› Inauguration of the Christophe and Rodolphe Mérieux auditorium

The Christophe and Rodolphe Mérieux auditorium is a new facility encouraging innovation and collaboration between researchers and all types of doctors within the Centre Léon Bérard. The construction and fitting-out of this new building were made possible by the generosity of the Centre Léon Bérard's donors, with additional funding from the National Research Agency and the Centre Léon Bérard. Covering a total area of 453 m², this new building comprises an underground auditorium that can seat 197, areas for socialising, a cafeteria on the ground floor and a meeting room on the first floor.

In the cafeteria, the Centre Léon Bérard's catering service-provider SHCB has opened a snack bar, thus adding a new food outlet on the CLB site. The menu was drawn up together with Maison Têtedoie, which has supported the Centre Léon Bérard and SHCB for seven years now. ●



OCT.

› “Because every pain deserves our attention”

On World Day Against Pain, the Committee on Pain and Symptoms (CLUD'S) got busy raising awareness amongst patients and healthcare professionals about pain management. An exhibition designed by the CLB's pain specialists and the communications department was installed on the walkway, providing information on various topics: pain in children, procedure-related pain, postoperative pain, neuropathic pain and pain in home-based care, etc. Added to this incredible installation were workshops and a lecture.

The day was all about tackling preconceptions, giving patients a chance to have their say and expanding caregivers' skills. ●



› Care quality certification confirmed

The Centre Léon Bérard got the results back from the healthcare facilities certification report in November, five months after the experts visited in late June. The Centre has been certified “Care Quality Confirmed” with an overall score of 96.25% for meeting the specified standards.

We are proud of this most satisfactory result for our institution, and of the mobilisation and commitment our teams displayed during the visit.

In its conclusion, the National Health Authority, HAS, confirmed “the quality of care and awards certification for four years”. A new visit will be scheduled for the year prior to the expiry of the certification. In the meantime, HAS's main recommendations for CLB were to:

- › “Ensure the security and proper identification of high-risk medications at all stages of their distribution chain and across all departments,
- › Increase patients' awareness of their rights, particularly regarding advance directives and the possibility for them to write them,
- › Include user representatives in all matters concerning them and put the user project on a more formal footing. ”

Some corrective measures addressing the expert visitors' comments have already been rolled out, and others are under way. ●



DEC.

› The first “Assoc-ions nous” meeting!

In December 2025, we marked International Volunteer Day with the first meeting of the Centre Léon Bérard’s partner associations, an event organised by the Department of Legal Affairs and Patient Relations. After the Associations Forum, held in Hall 1 in September, those associations involved with our institution were back in the spotlight on December 10 and, through them, the voluntary work and commitment of former patients, friends and family, user representatives and volunteers. Some 15 people explained their projects and experiences helping others to an attentive audience of around 100. ●



DEC.

› Inauguration of the Thierry Philip Prevention Centre

On Tuesday December 16, the Centre Léon Bérard inaugurated a new building just for cancer screening and prevention as well as research into environmental causes: the Prof Thierry Philip Cancer Prevention Centre. This is the first facility in France to bring together preventive clinical work, health promotion initiatives and research teams studying major cancer risk factors, including those linked to the environment and lifestyle, under one roof.

The centre has been named after Prof Thierry Philip, a former Executive Director of the Centre Léon Bérard (1989-2009), as he was the first to introduce prevention work to the CLB, setting up departments devoted to prevention: Public Health, and later Cancer and the Environment.

Help in covering the cost of construction came from the Auvergne-Rhône-Alpes Region (€600,000), the state via the National Regional Planning and Development Fund (€500,000) and the City of Lyon (€150,000). The new centre covers a total of 1,351 m², spread across seven floors, and also has a rooftop terrace. ●

> More on page 21.



DEC.

› Treating bone tumours: the Centre des Massues and the Centre Léon Bérard, leading the way in France

The Centre des Massues, a French Red Cross medical-surgical and rehabilitation centre, and the Centre Léon Bérard have been working together on managing bone tumours through a joint care pathway for 10 years now. This long-standing partnership has resulted in the two centres becoming the leading national provider for treating malignant bone tumours in children, adolescents and adults, according to the latest 2025 Hospital Rankings published in December by the magazine *Le Point*.

The two institutions coordinate the care of patients of all ages with bone and soft-tissue cancers (which are rare and complex tumours accounting for less than 1% of all cancerous growths) through a shared patient care pathway. Not only is this cutting-edge expertise unique within the Auvergne-Rhône-Alpes region, it also positions the two institutions as the leading French player, and one of the top European players, in this field.

Each year, the two institutions treat some 100 adult patients and around ten children and adolescents with bone sarcomas as part of a coordinated care pathway.

The CLB and the Centre des Massues have set up a genuine two-site operation to provide this specialist service. The care pathway is based on multidisciplinary consultation meetings (MCMs) involving surgeons, medical oncologists, radiotherapists, radiologists and anatomical pathologists. The histological diagnosis is carried out at the Centre Léon Bérard. Depending on the location of the tumour, surgery may be performed by the surgical team at either the Centre des Massues or the CLB. Bone surgery takes place at the Centre des Massues, which has a dedicated technical facility, whereas soft-tissue surgery is mainly organised at the CLB. Drug protocols and radiotherapy are carried out at the Centre Léon Bérard. Supportive care is available at both institutions. Lastly, rehabilitation and physiotherapy, as well as providing any assistive devices should they be required, takes place at the Centre des Massues. ●



Caring for and supporting every patient

1. Prevention and screening

› Adapted physical activity for cancer sufferers: a new digital community to encourage patients to engage

The Centre Léon Bérard is the first French institution to offer Goove Community, a new feature from the Goove platform designed for patients taking part in adapted physical activity (APA). This online space offers patients an interactive and motivating environment, enabling them to access specialised content, interact with one another or with healthcare professionals, take on challenges and stay active in the long term.

Patients, caregivers, healthcare professionals and public health researchers at the CLB were closely involved in its development. Goove Community grew out of a shared observation in the field: there was a need for support that extended beyond hospital-based sessions, that would encourage social connections while boosting patient engagement in physical activity.

The digital platform offers simple tools that are accessible and designed to support them in their care pathway on a daily basis. ●

› A new consultation facility

The new Thierry Philip Prevention Centre offers personalised consultations to provide support based on the specific needs and circumstances of each person: cancer screening consultations (gynaecological, colorectal and dermatological) and prevention or support consultations (oncogenetics, nutrition, occupational cancers, post-cancer care, and prevention for family caregivers and individuals at increased risk of cancer, etc.). All this on one site, accessible from Boulevard Jean XXIII. ●

› ALDEBARAN: involving loved ones in the prevention pathway

The ALDEBARAN project was launched in August 2025 to devise and assess nutritional prevention intervention for breast cancer patients, while involving their informal caregivers in the process. Based on behaviour change theories, this initiative will compare the effectiveness of nutritional care involving informal caregivers with that of a conventional approach focused solely on the patient.

"The goal is twofold: to improve patients' eating habits and physical activity levels, while at the same time promoting a healthier lifestyle for their loved ones," explains Pauline Oustric, a public health researcher and project coordinator within the Cancer Prevention and the Environment Department at the Centre Léon Bérard. The plan is to assess 120 patient-caregiver dyads. Onboarding began in early August.

ALDEBARAN secured four years of backing from the National Cancer Institute (INCa) after it issued a call for "Prevent, Detect, Support: Before, During, and After the Illness" projects (SHS, PHIR).

This is the first time that a nutritional prevention project has included both the patient and their carer.

The goals of the ALDEBARAN project are:

- › To encourage a healthy lifestyle for patients and their family caregivers,
- › To reduce the risk of a relapse in the patient and the risk of cancer in the caregiver,
- › To develop a new care pathway that involves family caregivers in nutritional care, thus reducing the disconnect between primary and tertiary prevention.

IN FIGURES

119,042 consultations

11,125 video consultations

2,698 oncogenetics consultations

1,408 tobaccoology consultations

693 medical gynaecology consultations

153 consultations on the risks of occupational cancers

2025 data

2.

Diagnosing

A new block for diagnostics and interventional procedures

After many weeks of work, the new Block 1 opened its doors at the end of September 2025. Thanks to this reorganisation, the endoscopy, vascular access unit (VAU) and interventional radiology departments have now been brought together under one roof. This restructured technical facility comprises seven operating theatres and a post-anaesthesia care unit (PACU). It can manage up to 70 patients a day. This facility helps address one of the challenges relating to the time it takes to get a diagnosis from a biopsy, a matter that has long troubled the Medical and Scientific Project, notably by expanding diagnostic endoscopy services, regarding colorectal cancer screening in particular, as well as interventional endoscopy services. Block 1 is an integral part of the overall "operating theatre" facility, which includes 11 operating theatres (Block 3) and 1 brachytherapy unit (Block 2), making a total of 19 procedure rooms and 2 PACUs. ●

Installation of the new PET-Scan, uMI Panorama 35™

The LUMEN Centre is the nuclear medicine centre of the Hospices Civils de Lyon and Centre Léon Bérard Cooperative Healthcare Consortium. As part of its seven-year renewal programme, in August 2025 it installed one of the first uMI Panorama 35™ PET-CT scanners in Europe, and the only one in the Auvergne-Rhône-Alpes region. This new piece of equipment has a very low failure rate, making it very reliable. It is also more ergonomic and quicker, so patient comfort is greatly improved. The injected dose is approximately 20% smaller and the examination time cut by more than half, meaning radiation exposure for both the patient and the radiographer is lower with this CT scan. "We have gone from an acquisition time of around 10 minutes to four minutes; it is quite spectacular," says Dr Thomas Moggetti, the LUMEN Centre's coordinator of the nuclear medicine department. Purchasing this new PET scanner brings more than just technical improvements; the significant time savings mean workflows can be adjusted to better support the patient prior to the examination. ●



IN FIGURES

Radiology

Breast cancer

6,941 breast ultrasounds
6,544 mammographies
1,679 detections
1,357 breast biopsies performed under ultrasound guidance
220 stereotactic biopsies

Excluding breast cancer

13,937 scans
11,099 standard X-rays
10,702 MRIs
3,677 ultrasounds

Endoscopy

3,328 endoscopies performed
2,529 patients involved

Nuclear Medicine

11,710 diagnostic procedures
PET scans: 8,174
Gamma camera: 3,536 diagnostic procedures

2025 data

Pathobiology

100,375 slides made
25,279 anatomical pathology procedures
8,379 molecular biology procedures

Biological Sample Management Platform (PGEB)

Institutional collections or trials:

- Frozen tumours: 1,208 procedures (total 1,385 tubes)
- Prepared blood samples: 3,692 procedures (blood, serum, plasma, cells; an average of 3 aliquots, totalling 9,194 tubes)
- Derived products produced: 2,937 procedures (DNA RNA extracts; 3 aliquots on average with a total of 6,664 tubes)

Externally-sponsored clinical trials:

5 470 patients, for 20 600 samples (= procedures) received, following which nearly 38,718 tubes generated (stored temporarily until returned to the sponsors)

Collections preserved:

- Institutional collection: nearly 18,000 tumour samples and 48,000 blood samples can be made available to the medical and scientific community. In 2025, more than 17,000 samples were handed over for research this way.
- Collections housed: UNICANCER, MESOBANK. A total of some 682,000 tubes are stored at the CLB

Did you know?

The PGEB is ISO 20387 certified. This internationally recognised standard is a clear indication of the high quality of the resources and data made available to researchers.

Breakdown of cancers

* Active patient list. 2025 data

13,927 patients have been admitted or received outpatient care (chemotherapy, surgery and radiotherapy)

3,120 (22.4%) Breast

1,531 (10.99%) Digestive tract
Stomach, colon, rectum, gallbladder, pancreas, etc.

1,312 (9.42%) Soft tissues, bone and cartilage
Soft tissue tumours, fibrosarcomas, neurofibromatosis, Ewing's sarcomas, osteosarcoma, etc.

1,256 (9.02%) Respiratory tract
Lungs, bronchi, trachea, heart, pleura, etc.

1,180 (8.47%) Haematology
Myelomas, plasmacytomas, Burkitt's lymphoma, MNHL, ALL, etc.

852 (6.12%) Female reproductive system
Gonadal germ cell tumours, extra-gonadal germ cell tumours, cervix, uterus, vagina, etc.

822 (5.9%) Male reproductive system
Testicles, germ cell tumours, extra-gonadal germ cell tumours, testicles excluding germ cell tumours, prostate, penis, etc.

759 (5.45%) Upper aerodigestive tract
Lips, tongue, salivary glands, gums, roof of the mouth

724 (5.2%) Skin
Melanomas, naevi, skin (other histology)

522 (3.75%) Urinary tract
Wilms tumours, bladder, dome, kidney, renal pelvis, etc.

225 (1.62%) Central nervous system
Gliomas, oligodendrocytes, nerves, meninges, spinal cord, etc.

183 (1.31%) Endocrine glands
Thyroid, parathyroid, pineal, adrenal

64 (0.46%) Other locations
Lymph nodes, primary location unknown or poorly defined

35 (0.25%) Neuroblastoma
9 (0.06%) Eye
Retinoblastomas, eye, body, chamber, eyeball, etc.

1,333 (9.57%) Non-tumoral conditions

3. › Treatments



› Personalised medical care: understanding cancer treatments better thanks to the ProfiLER-02 study2

Launched in 2017 by the Centre Léon Bérard, the ProfiLER-02 trial compared the use of two gene panels to steer targeted treatments for cancer patients. The results of this study were published on April 7, 2025 in the prestigious science journal *Nature Medicine*.

The ProfiLER-02 trial offered molecular screening to 741 adult patients, both men and women, with solid tumours lacking identified therapeutic targets such as HER2 or EGFR. This meant the two different gene panels (one comprising 324 genes, the other limited to 87 commonly used genes) could be compared. The alterations were studied at the CLB's multidisciplinary molecular tumour consultation meeting so as to identify recommended molecular therapies. The primary evaluation criteria was the proportion of patients for whom a targeted treatment was identified and offered. Among the patients taking part, 45.7% had evaluable tumour samples. Targeted therapies were identified for 175 patients (51.6%) using the larger gene panel and for 125 patients (36.9%) using the smaller one. "We thus observed a significant increase of 14.8 percentage points with the most comprehensive gene panel compared to our usual, more limited panel, thereby meeting the primary evaluation criteria," explains Dr Olivier Trédan, medical oncologist and the study's principal investigator.

These results confirm the need to broaden the gene panels in order to increase the number of therapies tailored at the molecular level. ●

› Robot-assisted surgery

The first year of using the robot has been a success, with 212 robotic procedures being carried out across four specialities: thoracic surgery (59 procedures), gynaecological surgery (45 procedures), visceral surgery (102 procedures) and ENT surgery (6 procedures). These figures exceed projections made for this first year of use. ●

› Laparoscopic mastectomy

For the first time in Lyon, a bilateral, minimally invasive endoscopic mastectomy was performed in October 2025 in the CLB operating theatre by the breast surgery team. This innovative procedure is better for patients in several ways. Insufflating the surgical site with gas means the procedure can be carried out without skin tension, whilst the endoscope, fitted with a camera, provides optimal visualisation, facilitating accurate haemostasis using tissue-preserving instruments.

So this technique makes it possible to preserve the skin and nipple, resulting in better aesthetic and functional outcomes, particularly regarding post-operative pain. In addition, the risk of prosthesis displacement is reduced, as the scar is located further away from the prosthesis pocket (the site where the breast implant is placed within the body).

The main advantages of this technique for the patient are:

- › A smaller scar hidden under the arm or level with the armpit,
- › A shorter hospital stay,
- › Fast recovery. ●



IN FIGURES

Anaesthesia

9,357 consultations

6,486 different patients

8,566 anaesthetic procedures

3,601 insertions of venous catheters

Surgery

37,326 consultations

4,893 patients operated on excluding endoscopies and venous catheters

6,321 surgical procedures, excluding endoscopies and venous catheters

5,393 procedures under general anaesthetic

928 procedures under local anaesthetic

Radiotherapy

3,400 patients:

3,744 treatments started

› At the Centre Léon Bérard

2,626 CLB patients

18,436 conventional sessions

7,067 Versa HD© sessions

4,704 tomotherapy sessions

1,786 CyberKnife© sessions

› At Villefranche-sur-Saône

774 Villefranche patients

11,509 SESSIONS IN ALL

6,706 conventional sessions

4,803 tomotherapy sessions

Medicine

73,555 consultations

2,022 medical procedures

Pharmacy

€82.1 million spent on anti-cancer drugs

105,274 chemotherapy preparations

13,908 preparations for clinical trials



Nuclear Medicine

› Gamma camera

370 procedures

Interventional radiology

3,458 interventional radiology procedures

› Interventional radiology is used to treat cancer, in supportive care (pain management, nutrition, etc.) and also in diagnostics.

Cell therapy

› Peripheral haematopoietic stem cells

For the CLB

44 patients

77 cytopheresis sessions

For l'IHOpe*

13 patients:

22 cytopheresis sessions

› Lymphocytes for Car-T Cells

For the CLB :

39 patients

For l'IHOpe* :

2 patients

*Paediatric Haematology and Oncology Institute, a Cooperative Healthcare Consortium of the Hospices Civils de Lyon and the Centre Léon Bérard



2025 data



› Multidisciplinary Consultation Meetings (MCMs)

Cancer care is multidisciplinary, and involves all the medical institution's medical specialists. **Multidisciplinary Consultation Meetings (MCMs) are held on a weekly basis for every type of cancer pathology and every stage of the disease** During these meetings, surgeons, radiotherapists, medical oncologists, diagnosticians and supportive care professionals review the cases of each patient treated at the Centre Léon Bérard or at external hospitals in order to determine the most appropriate treatment protocol.

	Cases discussed	New patients	External cases
Sarcoma diagnosis MCMs	3,202	1,155	699
Bone and soft tissue diagnosis MCMs	2,125	1,524	660
Breast tumour MCMs	2,113	1,154	197
Gynaecological oncology and rare tumour MCMs	2,034	577	925
Lymphoid and myeloid haematology MCMs	1,956	1,020	1,118
Digestive tract tumour MCMs	1,953	681	196
Skin tumour MCMs	1,606	878	494
Thoracic tumour MCMs	1,563	616	224
ENT tumour MCMs	840	403	73
Molecular diagnosis MCMs	828	623	361
Urology MCMs + kidney cancers MCMs	646	521	679
Malignant bone lesion MCMs	429	279	80
Adolescents and young adults MCMs	307	152	207
TOTAL	19,602	9,583	5,913

4 › Types of hospitalisation and organisation

› Knowledge Carousel for self-employed professionals: First edition

The first knowledge carousel for self-employed professionals was held in November 2025. The day included interactive workshops and useful discussions. Educational workshops giving a comprehensive overview of key hospitalisation at home procedures were offered free to all private-practice nurses caring for Centre Léon Bérard patients. ●



› Trial of a flat-rate payment scheme for cancer treatment provided through healthcare at home services

The Centre Léon Bérard has been chosen to participate in a national pilot scheme, set up under Article 50 of the 2024 Social Security Financing Act, to trial a flat-rate payment model designed to encourage the administration of cancer treatments (chemotherapy or immunotherapy) in the patient's home through home-based care. Oral treatments are excluded from this trial. This pilot, scheduled to run for three years, will make it possible to assess a funding mechanism for hospital care coordination. The decree, published in February 2025, came into effect in August 2025. At the Centre Léon Bérard, we are all set up for this new care pathway. More than 100 admissions have taken place under this initiative since its launch. ●

› The importance of peer-support within the care pathway

The PROOF programme is a research project designed to assess the importance of peer support within the care pathway of patients treated for breast cancer at the CLB. PROOF has been rolled out in four facilities in France: the Hospices Civils de Lyon, the Greater Paris University Hospitals (Assistance Publique des Hôpitaux de Paris, or AP-HP), the Groupe Hospitalier Universitaire Paris Psychiatrie & Neurosciences (GHU) and the Centre Léon Bérard. The main goal is to evaluate the impact rather than the feasibility of integrating peer support workers into care pathways and to demonstrate the benefits of this approach for patients undergoing treatment, care teams and peer support workers. Peer support workers were enrolled in 2025; they are no longer undergoing treatment themselves and have completed a breast health training programme. They can be found at the CLB two days a week (Wednesday and Thursday) and have their own email address, phone line and meeting space.

Seven patients were brought into the programme on January 30, 2026. Lasting 24 months, it will include 72 CLB patients. The programme has two components: one will be exploring the effects of peer support on various cohorts, and the other will be identifying the factors that help or hinder the roll-out of peer support and studying context-related differences. The evaluations will be both quantitative and qualitative: a questionnaire sent out to the 72 enrolled patients, 3 peer support workers and 10 healthcare professionals; and interviews with 10 enrolled patients, 3 peer support workers and 10 healthcare professionals. ●

› The patient hotel: 97.9% of patients are satisfied with Maison Léon Bérard

Opened in 2021, Maison Léon Bérard (MLB) was one of the very first patient hotels in France. This type of accommodation is designed for independent patients who are undergoing treatment but do not require particular medical monitoring. The medical team may

offer this innovative solution to those who live far from Lyon and are undergoing regular treatment at the Centre (such as radiotherapy sessions), or those arriving for same-day surgery for example. But what do the guests think? Since it has now been running for five years and has undergone a major renovation funded by corporate sponsors, including Apicil, it seemed a good idea to measure the impact of Maison Léon Bérard on those whose

opinion matters most.

Thanks to support from Apicil, we were able to conduct an impact assessment in the form of a survey, and the results were more than positive. 97.9% of patients who stayed at MLB* were satisfied with their rooms and communal areas. And 96.6% said they felt less stressed during this part of their care. ●

*532 people were questioned between February and June 2025, 237 replies.



› In 2025, the CLB had 22 care coordination nurses (IDECs) in the care pathways:

'Adolescents and young adults', 'Skin tumours', 'Digestive tract and stoma care', 'Gynaecology', 'Haematology and transplants', 'Respiratory medicine', 'Geriatric oncology', 'ENT', 'Breast Medicine' and 'Urology'.

Tasks for IDECs were reorganised in order to create a pool. The new structure ensures continuity of patient care should an IDEC be absent or there be a vacancy, regardless of the care pathway involved.

As well as this reorganisation, we have expanded the monitoring programme to include patients with metastatic breast cancer. And by the end of 2025 a second specialised IDEC position had been created in geriatric oncology.

In 2025, IDEC involvement in clinical trials conducted at the CLB increased significantly, for example in the CANIQUOL (telemonitoring in urology) and AFTERGYN (supportive care in gynaecology) studies. ●

› Oral therapy at home

In late 2025, the Technical Committee on Health Innovation (CTIS) and the Strategic Council on Health Innovation (CSIS) issued a favourable opinion on the broad roll-out of Onco'Link, a pioneering pilot project led by Unicancer in which the Centre Léon Bérard participated. Between 2021 and 2025, close to 400 patients being treated at the CLB were enrolled in this pilot funding scheme (Article 51*). Incorporating this measure into general law paves the way for a new, sustainable funding model starting in 2027. This is something both medical oncologists and patients have been calling for very strongly. ●

* The purpose of Article 51 is to trial innovative organisations that use new methods of funding and organisation.

› Expanding telemonitoring

Launched in 2024 for patients being treated for breast and ENT tumours, telemonitoring was expanded to cover all care pathways in 2025. More than 300 patients have benefited from it. Telemonitoring is a means of monitoring a patient from a distance using a safe digital tool, so they don't have to travel. We are now exploring the possibility of hospitalisation at home IDECs using this system to improve the continuity of care from hospital to home. ●

IDEC ACTIVITY IN FIGURES

3 227 patients monitored daily (excluding geriatric oncology)


More than 30% of new patients monitored at CLB are monitored by an IDEC

17 669 calls and emails from patients handled (+7%)

7 468 calls and emails from caregivers or friends and family of patients handled (+11%)

HOSPITALISATION IN FIGURES

Admissions capacity



Conventional and outpatient admissions

11,265 conventional inpatient admissions

43,528 outpatient medical admissions (excluding UAMU**)

6,577 outpatient surgical admissions

5.36 average length of stay in days

** The Unplanned Admissions Management Unit

Continuous care

597 different patients

642 stays involving transfers

2 547 administrative days

4 average length of stay in days

87.2% occupancy rate

Provision of care at home

› Hospitalisation at Home (HAH)
2,044 patients
8,761 admissions

› Home-based care (HBC)
1,321 patients
1,551 admissions

2025 data

5. Supportive care and complementary care


The Centre Léon Bérard has put in place various complementary care and support activities to help patients and their families during the illness and treatments. Some of these initiatives are financed through CLB fundraising campaigns and support from the voluntary sector.

› The Supportive Care Department has turned 20

In 2025, the Department of Interdisciplinary Supportive Care of Oncology Patients (DISSPO) celebrated its 20th birthday. Several events were organised to mark the occasion: an exhibition, lectures and activity days for healthcare professionals and the patients. Since it was set up, DISSPO has played a central role in supporting patients, providing essential help to ensure their quality of life throughout the care journey. It serves as a vital link between various medical and paramedical specialties, bringing together committed, multidisciplinary teams that intervene at all stages of illness. Even before the department was officially created in 2005, the Centre Léon Bérard had been a pioneer in offering supportive and wellness care to patients in France. But each of these activities was carried out by professionals working in isolation from one another. In 2005, they were all brought together in a single department, facilitating communication and coordinated patient care. ●

› The dangers of falling: an in-house exhibition

The Centre Léon Bérard put together an exhibition that could be seen in various locations throughout the hospital from April 3 to May 5, 2025, to raise awareness about the risk of falls, not only among patients over the age of 65, but also caregivers and the general public. Each year, more than two million people over the age of 65 suffer from a fall in France. This risk also affects elderly cancer patients, for whom the already gruelling treatments make prevention all the more essential. To tackle this public health issue, the Centre Léon Bérard is launching an awareness-raising initiative aimed at patients and their caregivers. ●



IN FIGURES

› **3 193 patients** cared for by DISSPO, representing **24.1%** of the active list of hospitalised patients.



And **2,191 patients** treated by the physiotherapy team
2 728 patients monitored by social services

3,093 patients seen by the nutrition team

1,988 patients seen by the psychology team

1,024 patients given analgesia consultations

829 patients looked after by the mobile palliative care team

837 patients seen by the mobile analgesia nursing team

166 patients treated for chronic wounds

77 patients treated with photobiomodulation

77 cases studied as part of the MCM for complementary care

* Department of Interdisciplinary Supportive Care of Oncology Patients

Well-being Area

969 patients helped by specialist hairdressers

1,059 patients seen by specialist aestheticians

Adapted physical activity

2,107 patients supported

Meeting and Information Space (MIS)

› **1,450 visitors** **91% women** **9% men**

45% seeking information
45% listening and socialising

› Who comes to the MIS?

81% patients
10% friends and family
6% professionals (wigmakers, pharmaceutical laboratories, professionals for various therapies)
3% volunteers from associations, students

2025 data

› Therapeutic Education

› TEPF continues to grow as its team is strengthened

Thanks to patient outreach and numerous referrals by CLB professionals, the TEPF (Therapeutic Education for Patients and Families) programme grew dramatically in 2025 (with more than 1,000 people treated) and is now enjoying great success among patients. The TEPF team has continued its commitment to meeting with professionals and patients to explain the programme. Numerous professionals have attended workshops, helping raise awareness about this initiative, leading to improvements in patient referral practices.

And, in order to meet high patient demand throughout 2025, three new nurses joined the existing TEPF team. ●

› Restructuring of TPE care in 2025

Following the new recommendations from the regional health body, ARS-ARA, a Therapeutic Patient Education (TPE) pathway is now defined as an Initial Shared Educational Assessment, participation in at least three educational workshops and a Final Shared Educational Assessment. Plus, the involvement of carers in the workshops is now recognised. ●

› Bringing patient partners onto the TEPF team

In September 2025, a group was formed comprising patients who previously participated in TEPF workshops, who, having gained sufficient perspective of their condition, wished to get involved in supporting other patients. A first patient has begun her training in therapeutic patient education (a mandatory 40-hours in TPE) and will be able to co-run workshops starting in June 2026 alongside TEPF nurses. Including patient partners in TPE is completely in step with projects and initiatives led by the Department of Nursing, Rehabilitation and Medico-Technical Services (DSIMRT) as part of the Medical and Scientific Project 2026–2030. ●

IN FIGURES

1,008 underwent an educational diagnosis at the start of their care (Initial Shared Educational Assessment)

597 underwent an educational assessment at the end of the workshop (Final Shared Educational Assessment)

Individual and group educational workshops:

1,605 people attended workshops:

673 attended workshops related to **treatments**

313 attended workshops related to **nutrition**

248 attended workshops related to **stomas**

151 attended workshops related to **fatigue**

122 attended workshops related to **Adapted Physical Activity**

72 attended workshops related to **specialist aesthetics**

26 attended workshops related to **pain**

› Good to know:

Workshops can be in-person or remote, and some can even be held at home. The TEPF team can be called upon at any time during the patient's care, regardless of the disease involved.

2025 data

› The Addiction Treatment Liaison Team (ELSA)

› Short circuiting tobacco (the Circuit Rapide de Tabacologie, or CRT)

Set up in 2020, the CRT celebrated its fifth anniversary in 2025. CRT is a pilot project for new patients before they undergo surgery. The pilot's main goal was to assess the acceptability and feasibility of a rapid tobacco cessation intervention for patients who smoked and were scheduled for surgery following an initial cancer diagnosis. Before the programme was rolled out, all oncologists and surgeons involved were trained in the mechanisms of addiction and how to initiate nicotine replacement therapy (NRT), while medical assistants were also made aware of this

new care pathway. Some 281 patients took part in the study between November 17, 2020, and May 31, 2025; 62 declined the measure after it was presented to them, with 46% stating that they preferred to quit on their own. Results from the 217 patients who underwent NRT were encouraging: 68% of them stopped smoking before surgery (median quitting time before surgery: 17 days) and 76% continued with the therapy after surgery. The rate of those who had not resumed smoking after a year is comparable to that recorded in a similar study conducted by MD Anderson Cancer Center in Houston (43%). Nearly 80% of those who completed the entire programme were still not smoking after one year. ●

IN FIGURES

1,825 annual interviews held

Preoperative cessation data for 2025:

29 cases of pre-operative cessation indicated

12 refusals

10 pre-operative cessations with the Hôpital de l'Arbresle, as part of a hospital partnership

3 cessations at L'Arbresle, but not pre-operative





Innovating for all

6. Clinical Research

› FIRST-NEC: a collaborative clinical study model

The multi-centre FIRST-NEC trial, active in 31 French hospitals, is the result of a collaboration between Hôpital Nord-Ouest – Villefranche-sur-Saône (Dr Luc Odier, principal investigator), the Centre Léon Bérard (study sponsor) and the French Lung Cancer Group (GFPC).

Its aim is to prospectively assess the benefits of immunotherapy (durvalumab) in patients with advanced large cell neuroendocrine carcinoma of the lung (LCNEC).

Durvalumab is administered in combination with first-line chemotherapy, followed by

maintenance therapy. In all, 51 patients with a confirmed LCNEC diagnosis will be enrolled in the study over a 36-month recruitment period.

The primary goal of the trial is to study the progression-free survival of patients one year after treatment is initiated. The secondary endpoints will evaluate the radiological response rate, treatment safety and overall survival.

On an exploratory basis, efficacy data will be compared with an external control arm taken from real-world data from the Unicancer "ESME – Lung Cancer" database.

FIRST-NEC has already been the subject of a 'Trial In Progress' poster

presented at ASCO 2025 and a methodological article, pending the study's results later in 2027.

This study is being funded by the National Cancer Institute (INCa) and the Directorate General for Healthcare Provision (DGOS) as part of the hospital-based clinical research programme (PHRC-K23-033), with the support of AstraZeneca. It also includes an ancillary research programme being carried out with Cochin Hospital (Assistance Publique – Hôpitaux de Paris, AP-HP).

› PPI-Emulation: Causal inference from observational data

Numerous retrospective studies suggest a deleterious effect of proton pump inhibitor (PPI)* use on the efficacy of immunotherapies or targeted therapies in oncology.

The PPI-Emulation study is using the target trial emulation approach to confirm or refute this hypothesis. The principle involves explicitly specifying the key elements of the target trial protocol (the hypothetical pragmatic randomised trial we want to conduct to answer the causal question posed in this study) and then matching this protocol with the available observational data.

This observational data comes from Unicancer's "ESME – Lung Cancer" database, which contains diagnostic data, oncology treatments and clinical monitoring information. Access to Unicancer's HARMONIE health data warehouse will also make data on PPI consumption derived from the France's national health data system (SNDS) available.

Two separate clinical trials will be emulated to compare the effectiveness of immunotherapies versus tyrosine kinase inhibitors (TKIs) in patients with advanced or metastatic non-small cell lung cancer, with or without concomitant proton pump inhibitor (PPI) treatment.

The target trial emulation model, combined with advanced statistical methods, will mean that potential biases (selection, immortal time, information, confounding, etc.) can be effectively controlled to produce reliable results and robust recommendations regarding the use of PPIs in oncology.

This study, sponsored by the Centre Léon Bérard, is being conducted in collaboration with Unicancer and the Institut de Cancérologie de l'Ouest. It is financed by INCa and the DGOS as part of PHRC-K25-174.

An article describing the method used has been submitted for publication, and the final results are expected in late 2026.

* Medication for reducing gastric activity

MAI EN GRIS

DU GRIS À L'ARC-EN-CIEL : ENSEMBLE CONTRE LES CANCERS DU CERVEAU !



› TARLATEM: a collaborative paediatric and adult CLIP² clinical trial evaluating immunotherapy and chemotherapy for high-grade brain tumours.

This trial is being coordinated by Dr Pierre Leblond, a paediatric oncologist, in collaboration with Dr Aurélien Maureille, a neurologist, for the adult component. The Centre Léon Bérard is sponsoring it. This study is funded by INCa and the ARC Foundation as part of the CLIP² programme (accredited early-phase centres), with support from Amgen.

TARLATEM is a multi-centre Phase I-II trial evaluating an innovative combination therapy for relapsed high-grade brain tumours in adolescents aged 12 and older and adults after standard treatments failed (NCT07243470).

It is evaluating the combination of two treatments:

- › Tarlatamab, a bispecific antibody immunotherapy known as "BiTE" for Bispecific T-cell engager, which simultaneously targets the DLL3 (Delta-like ligand 3) protein expressed on the surface of tumour cells and the CD3 receptor on T-cells. By binding to both targets at the same time, tarlatamab creates a sort of physical bridge between the tumour cell and the T cell, forcing the latter to recognise and destroy the cancer cell.

- › Temozolomide (TMZ), an alkylating agent already a standard drug in brain tumour management, is administered continuously at a low, metronomic dose to prepare the tumorous immune environment to respond to tarlatamab.

Prior to being included in the treatment phase, DLL3 expression is characterised using immunohistochemistry on archived tumour tissue, as part of a centralised analysis performed at Prof David Meyronet's laboratory (Hospices Civils de Lyon – Institute of Pathology, East Site). Only patients with a high-grade, DLL3-positive tumour are eligible to start this treatment.

The trial comprises two sequential stages: an initial exploratory tolerability stage so as to establish the tolerability of the combination, followed by Phase II in which clinical activity is evaluated in three distinct cohorts:

- › IDH-mutant high-grade gliomas,
- › Non-IDH-mutant high-grade gliomas,
- › Other high-grade brain tumours.

The population is set at 117 patients, enrolled from some 15 investigative centres in France, with the support of ANOCEF (Association of French-speaking Neuro-oncologists). ●

IN FIGURES

› **2,668 patients** included in clinical trials (all types of trials),
i.e. 19.1% of the active list

507 trials open for enrolment (302 active)

CLB-sponsored trials:



- › **All types of research:**
75 (45 active)
- › **Trials:**
59 (42 active)

Interventional research:

- › **446** interventional research studies (291 active)
- › **1,852** patients included in interventional research

150 early phase I and II (108 active)
56 phase I trials (47 active)

420 patients included in PP I and II,
157 of which in phase I



2025 data

7. > Translational research

> Cancer and AI

The Centre Léon Bérard is boosting its commitment to responsible, ethical and human-centred artificial intelligence, aimed at helping patients and healthcare professionals. AI is a major lever for improving care pathways, supporting medical decision-making, and optimising healthcare professionals' use of time.

In 2025, two structural projects supported by the France 2030 programme stand out in particular: **ESPACE** and **PARTAGES**. These initiatives are in lockstep with the national strategy to accelerate digital health and are evidence of the Centre Léon Bérard's ambition to actively contribute to health innovation alongside national partners.

ESPACE (whose full name translates as "patient-centred trials for advancing AI in cancer care"), led by the Centre Léon Bérard in partnership with the Caen and Lille centres and the CREATIS laboratory, offers a third place for digital health trials. It provides a secure framework for evaluating AI solutions in cancer care under "real-world conditions", bringing together patients, healthcare professionals, researchers and industry representatives. ESPACE aims to speed up the deployment of 5P medicine in oncology (personalised, predictive, preventive, participatory and proven) and to prioritise the long-term integration of tested innovations into clinical practice.

PARTAGES, coordinated by the Health Data Hub, explores how generative AI and large language models help facilitate the work of healthcare teams. The project develops and makes available synthetic medical data corpora, models and tools designed to improve the structuring and summarising of medical information on an open-source basis. This helps reduce the medical-administrative burden, freeing up medical time for the benefit of patients.

These projects underscore the Centre Léon Bérard's position in developing AI that is evaluated, secure and useful, in the service of excellence in cancer care. ●

> The first ever "CLB meet-ups: Innovation in Digestive Oncology"

On Friday, September 12, 2025 the Centre Léon Bérard held its first **CLB meet-ups: Innovation in Digestive Oncology**.

This event, organised by Prof Aurélien Dupré and Dr Clélia Coutzac, was aimed at healthcare professionals in the Auvergne-Rhône-Alpes region involved in treating patients with digestive cancers: gastroenterologists, gastrointestinal oncologists, radiotherapists, surgeons, radiologists and clinical research coordinators.

The day provided a chance to discuss the latest **developments in digestive oncology, open-label therapeutic trials** and **current innovations** in the region's various centres.

A round table discussion provided an opportunity to compare perspectives on access to therapeutic innovation with Dr **Jonathan Olesinski** (CH Villefranche) and **Cyril Sarrauste**, representing the colorectal patient network *Patients en Réseau – Mon réseau Colorectal*. This highlighted both the strong points and areas for improvement within our network, with the aim of streamlining the patient pathway.

This first edition concluded with a firm commitment to **strengthening regional collaboration** and ensuring the meet-ups became a regular feature. A second one is already planned for 2026. ●



> SIRIC LYriCAN+ midpoint evaluation

The SIRIC* LYriCAN+, a translational research programme of excellence led by GCS LCU under the scientific coordination of Prof Jean-Yves Blay, reached its midpoint in June 2025.

The LYriCAN+ certification began on January 1, 2023 for a period of five years, so the programme reached its midpoint in June 2025. There were two parts to the SIRIC evaluation process: an activity report submitted to INCa in mid-July, followed by an oral evaluation before an international scientific advisory board in December 2025. Recommendations were issued to all SIRICs, and others specifically to each individual SIRIC. The evaluation highlighted the excellence of LYriCAN+, with ideas suggested for continuing integration efforts and working with patient associations.

For this midpoint evaluation, the LYriCAN+ management team brought together the SIRIC's institutional partners and INCa representatives on July 1. This provided an occasion for the director and the leaders of the three Integrated Research Programmes (IRPs) to explain the progress the programmes were making, how they linked to interdisciplinary issues, and key highlights. ●

* Integrated Cancer Research Site

> ErVimmune raises €17 million to develop its anti-tumour vaccine

ErVimmune, a biotechnology company spinoff from research conducted at the Centre Léon Bérard and the Lyon Cancer Research Centre, managed to raise €17 million in 2025. The funds were secured from a consortium of international investors and will enable the company to enter a new phase in developing its lead anti-tumour vaccine candidate, ErVac01. ErVimmune can now conduct an initial clinical trial, a crucial step in establishing the safety and immunogenicity of this new therapy. ErVac01 will mean "cold" tumours such as triple-negative breast cancer or ovarian cancer, which are not very sensitive to immunotherapies, can be targeted. ●

IN FIGURES

6 priority patents filed
1 licence signed with industrial partners

4 start-ups hosted

85 new collaboration contracts signed

20 participations in European projects
1 CLB sponsorship = EURACAN

37 academic collaborations signed
49 industrial collaborations signed

63 agreements for the transfer of biological samples

187 replies to calls for projects

36% success rate in calls for projects

2025 data

8. Basic research

› The CRCL, a world class research centre

In January, the Cancer Research Centre of Lyon (CRCL) hosted its international Scientific Advisory Board as part of an audit prior to the centre's official evaluation by the High Council for Evaluation of Research and Higher Education (Hcéres). Composed of nine researchers, renowned worldwide for their work in the field of cancer research, the board was tasked with evaluating the effectiveness of the CRCL's organisation and structure, as well as auditing all its research teams.

The report issued by the board highlights the quality of the work carried out in recent years to structure the CRCL, which is now a world-class research centre. It also emphasises the quality of a work environment that encourages collaboration, and expresses a positive view regarding the scientific projects of the 22 research teams applying for inclusion in the CRCL's upcoming organisational structure, even citing several as having "exceptional potential". ●



› Launch of a new computational biology department

The recent roll-out of new experimental technologies, such as spatial omics and single-cell techniques, has enabled researchers to generate truly staggering volumes of data. Access to this data, combined with the use of artificial intelligence, suggests an acceleration in identifying relevant biomarkers and designing new treatments.

In response, the research management teams at the CLB and CRCL launched a new computational biology department in early 2025. This discipline focuses on developing and applying data analysis methods, mathematical modelling and simulation techniques for studying biological systems. ●



› The sixth CRCL International Symposium

The CRCL held its sixth international symposium on academic research into cancer on January 29-31, 2025.

Over the course of two and a half days, nearly 700 participants from France and abroad attended more than 30 lectures given by guest speakers or those chosen based on abstracts. Distinguished guests included Dr Joan Massagué (Director of the Memorial Sloan Kettering Cancer Center, USA), Prof Elaine Fuchs (the Rockefeller University, USA), and Prof Jean-Yves Blay, Executive Director of the Centre Léon Bérard.

After more than a decade of existence (the first edition was in 2013), the CRCL International Symposium is now recognised as the flagship conference on cancer research in France. ●

› Scientific excellence: the CRCL management is rewarded by the Foundation for Medical Research

Patrick Mehlen and Véronique Maguer-Satta, Director and Deputy Director of the Lyon Cancer Research Centre respectively, were both honoured at the annual gala of the Foundation for Medical Research.

Patrick Mehlen was awarded the FMR's Grand Prix 2025. This is an annual distinction, given to an internationally renowned person in the scientific community for their exceptional contribution to the advancement of scientific knowledge in the medical field. Patrick Mehlen received the honour for his body of work on dependence receptors, spanning from their discovery at a basic level in 1998 to the development of new associated therapies that are currently showing promising potential in clinical trials.

Véronique Maguer-Satta won the Prix Lucien Tartoïs. The purpose of this prize is to fund research in oncology, immunology or virology. Véronique Maguer-Satta leads a team studying how a group of proteins known as BMPs, bone morphogenetic proteins, regulate the signalling system between stem cells and their environment. By developing a 3D model of human bone marrow, the team demonstrated that abnormalities in this channel could boost the development and aggressiveness of tumours, and even alter the response to treatments. ●

› Endometrial cancer: a strategic collaboration with GSK

Launched in 2025, the BATON project is the result of a collaboration between the pharmaceutical laboratory GSK and the Lyon Cancer Immunotherapy Laboratory - LICL (CLB-CRCL). This partnership was made possible by several years of communications and a strong, trust-based relationship.

This project's goal is to better understand endometrial cancer by studying a new targeted therapy developed by GSK. Researchers are particularly interested in how this treatment affects the tumour



micro-environment and immune responses.

Thanks to close scientific collaboration between GSK's worldwide R&D department and the LICL (led by Dr Uzma Hasan and Dr Christophe Caux), BATON brings together a range of expertise in immunology and oncology. For the first time, all of the LICL's

IN FIGURES

325 CLB + CRCL scientific publications

186 CRCL scientific publications of which **44** in IF>10 journals

573 members of the CRCL: of whom **194** are researchers and teacher-researchers

36 different nationalities at the CRCL



lines of research, as well as several CLB-CRCL technology platforms (including the 3D-ONCO platform), are being mobilised.

The work is based on several types of data and analyses: clinical data from the CLB, immune system studies, blood analyses and laboratory-based 3D models that replicate tumours (organoids). The aim is to generate essential knowledge to prepare for future clinical trials of the treatment GSK is developing.

Lastly, a more ambitious, three-year project is in the pipeline. This will make it possible to prolong this work by linking feasibility data to patient immune monitoring as part of a major future clinical trial led by Prof Isabelle Ray-Coquard. ●



9. Education and training

THE TRAINING INSTITUTE

As part of its 2021-2025 project, which is included in the Centre Léon Bérard's strategic initiative, the Institute is looking to strengthen its current range of courses by adding new topics, developing new means of learning, such as e-learning and creating a new basic training course for medical secretaries, which will eventually be submitted for inclusion in the National Register of Professional Certifications. The Institute plans to open its courses up to an international audience (preceptorship).

► Highlights

In 2025, the Training Institute finalised its tender process for a new course management platform. The aim is to broaden the courses it can offer through the use of e-learning. This should start being rolled out during 2026.

Also in 2025, the Training Institute submitted an application to France Compétences to have its medical secretary basic training course added to the National Professional Qualifications Register (RNCP).

Since it began in 2022, 59 people have graduated from this certified degree course which currently has seven students. There are two sessions per year: one in April and one in October. ●



IN FIGURES

- 33** courses offered
- 55** training sessions
- 299** people trained
- including **43** doctors:
 - **15** anaesthetists
 - **7** dental surgeons
 - **7** nuclear medicine specialists
 - **6** radiotherapists
 - **3** pharmacists
 - **3** hospital practitioners
 - **1** oncologist
 - **1** Accident & Emergency doctor
- 168** teachers (including **130** CLB)
- 2 129** teaching hours
- 22** courses delivered including 5 ANDPC-accredited courses

2025 data

HIGHER EDUCATION

› First UPLIFT School



In November 2025, the CLB held its first “UPLIFT School” session. Some 50 people, including 19 doctoral students, were present. Since 2024, the Centre Léon Bérard has been a partner in the UPLIFT project, a doctoral organisation coordinating the activities of Europe’s Marie Skłodowska-Curie Action (MSCA Doctoral Networks), bringing together 15 European scientific, hospital and institutional partners. This project is dedicated to developing innovative solutions for treating patients with radiotherapy in an upright position. In France and at the CLB, two PhD students are involved in this project, each supervised by Prof Vincent Grégoire, Director of the Radiotherapy Department, and Lionel Perrier, a health economics researcher. The first deliverable with which CLB was tasked as part of this project was holding a doctoral school week. The six-day programme brought together the 25 students trained under UPLIFT and featured 25 specialists (physicists, radiotherapists and researchers from the European network or other institutions). The programme covered a range of topics. ●

› University and inter-university degrees run in conjunction with Claude Bernard University Lyon 1, open in 2025

› UD* in senology:

5 sessions of 2 days each per academic year, open in September 2024 for 2024-2025

› IUD** in oncogeriatrics:

5 sessions of 2 days each per academic year, open in September 2024 for 2024-2025

› IUD in acute and chronic pain and paediatric palliative care:

5 sessions of 2 days each per academic year, open in September 2024 for 2024-2025

› IUD in supportive care in oncology:

3 sessions of 5 days each per academic year, open in September 2024 for 2024-2025

› European IUD in surgical practices in oncology:

7 sessions of 2 to 3 days of teaching per academic year, of which 2 run by the CLB, open in September 2024 for 2024-2026

› IUD in respite and support for informal carers:

4 sessions of 2 days each per academic year, open in September 2024 for 2024-2025

› IUD cancer in adolescents and young adults (AYA):

2 modules of 2 days out of 6 held at the CLB, open in September 2024 for 2024-2025

*UD: university degreee **IUD: inter-university degree

IN FIGURES

- 16 university teachers:
 - › 6 assistant clinical directors
 - › 10 university professor-hospital doctors (PUPHs)
- 83 non-university doctors and nurses involved in university teaching
- 23 medical forums organised
- 4 clinician/researcher meetings organised
- 95 courses and clinical cases/teaching sessions in the 2nd cycle of medical studies
- 154 courses /teaching sessions in the 3rd cycle of medical studies

DOCTORAL SCHOOL AND MASTER’S DEGREE IN CANCER

Lyon has offered a comprehensive range of higher education courses in the fight against cancer since 2023:

- › a CanBioS doctoral school (Oncology, Biology, Health), created in 2023,
- › a Master’s in Cancer (created in 2013).

› The CanBioS Doctoral School

Administratively part of Claude Bernard University Lyon 1, this is Lyon University’s 18th doctoral school. The Cancer Research Centre of Lyon (CRCL), the CLB’s departments of Cancer Prevention and the Environment, Translational Medicine, and Human and Social Sciences, as well as LUMEN (the HCL-CLB Department of Nuclear Medicine), are affiliated to CanBioS.

This new doctoral school now welcomes some 150 PhD students. Its Director is Prof Caroline Moyret-Lalle, aided by Deputy Director Prof Agnès Bernet.

In 2026 it has some 160 HDR students. HDR is a French post-doctoral degree accrediting a person to supervise research. ●

› Master’s in Cancer 2025-2026

Created in 2013 as part of the Cancer Research Centre of Lyon (CRCL) and the Excellence Laboratory (LabEx) DEVweCAN, the Master’s in Cancer course is the only one in France to offer a comprehensive oncology curriculum in years 1 and 2 (M1 and M2).

In 2026, the Master’s in Cancer includes one year of M1 and three M2 specialisations:

- › M1 Cancer: 52 students, including 3 work-study students, including one at the CRCL
- › M2 Biology of Cancer: 32 students
- › M2 Therapeutic Innovation in Cancer Care: 24 students
- › M2 Cancer Bioengineering: 13 students ●



CONTINUING TRAINING

- 1,704 people took at least 1 training course in 2025
- 3,759 study leaves (one or more training courses)
- 2.71% of gross payroll devoted to continuing professional training
- 35,892 teaching hours

10. Social and environmental policy

› Employer brand: the difference

The Centre Léon Bérard launched its employer brand in 2025, following an audit conducted the previous year among managers and staff throughout the entire institution. This strategic initiative is part of the 2021–2025 Social and Management Plan, intended to boost the organisation's appeal as an employer.

This tool, also known as the "employer promise," is structured around five commitments grouped under the theme "Choosing Difference".

Joining the Centre Léon Bérard means choosing to work differently, because it means:

- › 1. Carrying out work that matters and where everyone matters.
- › 2. Having enriching experiences every day.
- › 3. Enjoying work within a friendly community.
- › 4. Building a career and growing within a learning structure.
- › 5. Having work/life balance.

These commitments were co-developed with teams on the ground to truthfully reflect the reality experienced by staff members, their expectations, and the values that drive the Centre Léon Bérard on a daily basis. ●



› A proactive HR policy: mental health prevention

In a hospital environment in which there are such high emotional demands, grave responsibilities and where the daily workload is intense, safeguarding employees' mental health is a major issue. Healthcare professionals, as well as medical-technical, administrative and logistics staff, face complex and sometimes harrowing situations on a daily basis, and this can impact their psychological well-being and quality of work life.

Protecting the mental health of professionals means not only caring for those who care for others, but also ensuring the continuity, quality and safety of care.

In 2020, the Centre Léon Bérard began rolling out a

proactive policy regarding mental health prevention and support, through a range of initiatives that all employees can access:

- › an in-house and on-site occupational health service for the CLB,
- › a social worker present twice a week,
- › online helpline services through partnerships.

To complete the initiative, in 2025 Mental Health First Aid (MHFA) training was added to the in-house training catalogue, with a module specifically designed for managers. A weekly on-site occupational psychologist surgery was also created. The aim of this free, confidential service, open to all employees, is to provide a space for listening and discussion regarding the professional situations encountered. ●

› The signing of the City of Lyon's Climate Pact

The Centre Léon Bérard signed the Climate Pact and a cooperation agreement, as part of the Lyon 2030 project, during a ceremony held at City Hall on November 5, 2025. "Since 2023, the City of Lyon has been spearheading a territorial pact, working in consultation with numerous local stakeholders, including the CLB, to which these stakeholders are invited to collectively commit," explains Julien Lapous, Energy and Ecological Transition Project Manager, who took part in the workshops to draft the Charter. By 2030, the Centre Léon Bérard will roll out various measures to drive a significant transition towards carbon neutrality. These actions will include the energy-efficient renovation of buildings, using renewable energy by installing photovoltaic panels, reducing waste and promoting sustainable, locally-sourced food. These actions will also improve quality of life at work, reduce energy costs and strengthen the example the institution is setting in terms of the fight against climate change. ●

› Launch of eco-care working groups

The first four eco-care working groups were created in 2025. Their role is to think up and put forward practical initiatives within their respective areas of responsibility to strengthen and promote our institution's commitment to the environment.

- › Eco-block (operating theatres and endoscopy): reduce waste by replacing Betadine with Chloraprep; use tie-up patient gowns rather than cut-away ones; and reduce water consumption by optimising flushing procedures.
- › Eco-tech radiotherapy (imaging and radiotherapy): boost and promote an optimised care pathway involving fewer radiotherapy sessions, thereby reducing the need for patients to travel, whilst maintaining the quality of care for patients; suggest a scientific paper assessing its impact.
- › Sustainable care (care teams): improve the sorting and management of waste generated by healthcare activities.
- › Climate doctors: assess and reduce medication waste.

IN FIGURES

› Recycling at the CLB

36 tonnes of paper and cardboard

0.8 tonnes of polystyrene

15 tonnes of wood

0.6 tonnes of glass

0.5 tonnes of ink cartridges

571 tonnes of household waste

5 tonnes of electric/electronic waste

64 tonnes of ordinary industrial waste

467 plastic bins

615 tonnes of potentially infectious medical waste (PIMW)

11. National and International Partnerships

› A stronger partnership with Bourg-en-Bresse Hospital

As part of its role as a regional referral and specialised care centre for cancer care, the Centre Léon Bérard is continuing to support healthcare facilities throughout the region, in order to strengthen local care delivery in health catchment areas where needs are rising but the medical workforce is stretched.

With the active caseload of cancer patients up by nearly 40% in a year, the Bourg-en-Bresse catchment area, where the departments of Ain, Jura, and Saône-et-Loire meet, is facing a surge in demand that is difficult to meet given its limited medical resources. So Bourg-en-Bresse hospital and the Léon Bérard

Centre have committed to strengthening the existing medical oncology pathway, as well as establishing a gynaecological cancer surgery pathway. This move is being backed by closer collaboration on clinical trials, with a view to improving access for patients in Bourg-en-Bresse to trials being conducted at CLB, particularly for patients with breast and ovarian cancer. Innovative work has also started on facilitating patient referrals to clinical trials offered at facilities in the region and in the Swiss border area, through the EU-funded Trial Match project (an INTERREG project).

This is how the Centre Léon Bérard helps both strengthen local networks and improve access to innovation for cancer patients in the region and across the border. ●

› The patient experience is taking shape

In November 2025, a larger users' committee was established. This new body brings together patient representatives, healthcare professionals from the Centre Léon Bérard and members of the "Regards croisés" Group. Established in 2018, it is made up of former patients and their family and/or caregivers. The "commission des usagers élargie", or CDUE, will meet four times a year. Its role is to review major projects that are under way and enable users to organise working groups on topics they deem priorities, with the aim of producing a "Users' Project".

The CDUE complements existing bodies: the Users' Commission, which continues to meet monthly to review complaints, and the Patient/Caregiver Experience Committee, which looks at and gives its opinion on the processes and tools in place across all CLB department projects involving patient partners or caregivers. The members of these bodies thus contribute to improving the quality of care for patients and caregivers through projects, ideas and innovative organisational suggestions that involve patient partners and caregivers. ●

› The Trial Match 2 project in the spotlight!

During the 36th edition of the Trophées du Commerce on June 2, 2025 in Geneva, TM2 was given the Swiss expansion into France award.

The project, launched in 2023 between CLB and Geneva University Hospitals (HUG), is led by Prof Alfredo Addeo, Head of the Oncology Department at HUG, and CLB oncologist Dr Loïc Verlingue, in collaboration with the companies Coexya and Qim Info. Its goal is to improve patient care in cross-border areas by facilitating access to clinical trials. It receives financial support from Interreg France-Switzerland, an EU programme co-financed by the European Regional Development Fund (ERDF), the Swiss Confederation and the cantons.

The collaboration between HUG and the CLB was recognised by the CCI France Suisse chamber of commerce and industry (CCIFS) through this prize for the TM2 project. And Prof Olivier Michielin (HUG) was there at the award ceremony to collect it. TM2 highlights a collaboration based on a unique model of cooperation in the fight against cancer, based on pooling medical, scientific and technological expertise. ●



IN FIGURES

International patients

716 requests in 2025
(up 42% on 2024)

186 quotes sent

148 quotes accepted:

- › **19** anapath reviews
- › **22** MCMs for European patients referred by the Unit
- › **45** video consultations

› What stood out this year was the increase in activity and dealing with more complex cases. New requests are systematically directed to the online form, and the processing fee has to be paid upfront in order to control the flow and optimise application management.

62 patients
came to the CLB:

- 25** for follow-up consultations
- 21** for radiological or endoscopy exams
- 6** for chemotherapy treatment
- 6** for surgery
- 4** for radiotherapy

2025 data

12. Communication



CLB Prevention Campaign – 2025

Website

215,000 unique visitors in 2025 (up 4.37% compared to 2024)

747,000 pages views in 2025 (up 2.75% compared to 2024)

54 news items published and **54** more pages added to the website

863 requests for information from patients, friends and family, healthcare professionals, students, companies, and the general public were handled by the communication service, in conjunction with the Meeting and Information Space (MIS).

In-house communication

6 in-house magazines published, **116** institutional emails and newsletters sent to employees

4 meetings for new recruits

12 in-house events, including the Christmas Market



Press Relations

The Centre Léon Bérard was mentioned in **1,234** articles in the print and digital press, as well as in audiovisual media reports.

95 journalists' requests handled

36 press releases and information sent out

2 press events organised for the inaugurations of the Christophe and Rodolphe Mérieux Auditorium and the Thierry Philip Prevention Centre.

Events

The Centre Léon Bérard organised:

18 events in 2025 for patients/ friends and family + **8** conferences

2 institutional events

Social Media

› LinkedIn :

30,748 followers (up 22.47% or **5,641** new followers)

213 posts

› TikTok :

29,743 followers (up 19.64% or **4,882** new followers)

54 posts

› Facebook :

17,025 followers (up 18.53% or **2,437** new followers)

469 content posts without stories

› Instagram :

7,090 followers (up 22.37% or **1,296** new followers)

409 posts with stories

› YouTube

CLB institution channel:

7,143 followers (up 1,446);

235.3k views;

30 videos posted

Healthcare professionals channel:

1,048 followers (up 248);

46.5k views;

6 videos posted

13. Fundraising

› Donations and bequests in 2025

A total of €15,225,287 was received in the form of donations and bequests.

This represents the entirety of donations and bequests made over the course of the year by individuals, associations and companies, etc. The money helps fund innovation in cancer research as well as supportive care for all patients – adults, adolescents and children.

The figures detailed further on are from the "Annual statement of use of resources collected from the public" shown on pages 60-61 and certified by the auditors. ●

› 2025 donations:

€9,191,950

(up 9.1% on 2024)

Thanks to the efforts of more than 45,000 donors (individuals, companies, associations and foundations, etc.), donations received in 2025 amounted to €9.192 million.

The generosity of our donors enabled us to set a new record and increase funds raised this way by almost 10% compared to 2024. ●

› 2025 bequests:

€6,033,337

(up 49% on 2024)

This sum refers to the sale of assets bequeathed to the Centre Léon Bérard such as movable property and real estate, or financial products like life insurance, during the year. The sum can vary enormously from one year to the next, depending on sales made or cash available through life insurance policies, for example. ●




› Fundraising and operating expenses

In 2025, these overheads amounted to just 8% of the total funds raised from the public.

- › €749K was to cover the cost of putting together appeals for donations from the public (telephone fundraising campaigns, mail shots, emails, events and websites), as well as donor management software and issuing tax receipts, etc.
- › €489K including €42K in administration fees relating to bequests (service charges for bequeathed properties, invoices for repairs and maintenance of these properties, clearance costs, local taxes and grave maintenance, etc.). The remaining portion was spent on salaries for all those working in the donor relations department. ●



IN FIGURES



45,700
supported

the CLB teams with one or more donations during the year.

Of these, more than **44,700** were individual donors making donations that would offset their income tax or property wealth tax. More than 10% of them donate by direct debit.

› What these donations made possible

This year, €6,418,640 went towards the research carried out at the Centre Léon Bérard, and €351,291 went on supportive care projects for adult, adolescent and paediatric patients.

Here are just a few examples of how we used the funds in 2025.



€3,967,297



€758K

› Inauguration of the Christophe and Rodolphe Mérieux auditorium

After almost three years of hard work, the Christophe and Rodolphe Mérieux Auditorium was officially inaugurated in October 2025. Covering a total area of 453 m², this new building comprises an underground auditorium that can seat 197, and areas for meeting and socialising.

This is a new facility, within the Centre Léon Bérard, encouraging innovation and collaboration between researchers and doctors of all disciplines and nationalities. More than 50 scientific events were organised there during the first six months of the fiscal year, including some international ones, strengthening the leading role the Centre plays as a host for the scientific community.

The construction and fitting-out of this new building were made possible by the generosity of the Centre Léon Bérard's donors, including the Christophe and Rodolphe Mérieux Foundation, with additional funding from the National Research Agency and the Centre Léon Bérard. ●

› Overview of donors to the CLB

€2,176K

from more than 500 companies, foundations or endowment funds by way of corporate sponsorship.

€5,538K

from the generosity of more than 44,700 individual donors who support the Centre's teams through one or more donations per year.



€1,448K

thanks to nearly 300 associations, large and small, that support our work by making donations or organising events to help the Centre's research and care teams.*

€30K

from the 150 municipalities in the region that voted through a grant to support the Centre and its public interest missions.

*This sum does not include funds received through calls for projects.

› 48 positions connected to research and patient support programmes funded

More specifically, these are 48 full-time-equivalent positions, mainly in the field of research: post doctorates, lab technicians and clinical research associates, etc. These posts also involve basic, translational and clinical research, adapted physical activity and PASCA (Cancer Care Pathway), etc. Donations and bequests enable us to recruit new members of staff to strengthen teams or launch new projects, bridging the gap until longer-term funding can be secured. Positions related to patient support, such as the work of a special aesthetician or of adapted physical activity instructors, are also funded thanks to donations. ●



€351,291

› Improving the daily life of the Centre's patients


Patient comfort and quality of life are a top priority at the Centre Léon Bérard. Patients are offered holistic support, in addition to their medical care. The aim is to be there to help them cope with their cancer better, whether during or after treatment. Thanks to donations, we are able to offer free care and activities, such as specialist aesthetics workshops, hairdressing, foot reflexology, psychomotor therapy and adapted physical activity, year after year. Musical, artistic and recreational activities for children receiving care at the Paediatric Haematology and Oncology Institute (IHOPe) are also made possible, not to mention buying gift cards for the holiday season. ●



€24K

› More renovation work on Maison Léon Bérard

Located 600 metres from the Centre, Maison Léon Bérard is one of the very first patient hotels in France. With 30 rooms, welcoming communal areas and a garden, it offers patients undergoing regular treatment a lovely place to stay away from the hospital, while remaining in immediate proximity to the medical teams. Renovation work has been continuing thanks to backing from donors and corporate sponsors. In 2025, one area was completely renovated to provide patients staying at Maison Léon Bérard with a room dedicated entirely to adapted physical activity. Work on this space is continuing, with a view to its inauguration sometime in 2026. ●



€725,205

› Two complementary pieces of equipment for precision research

Two new pieces of research equipment, funded entirely by donations, were added to the research laboratories at the Centre Léon Bérard in 2025.

The purchase of a NocoCytte Opteon UVBYR spectral flow cytometer and an Incucyte S3 HD/2CLR imaging system marks a strategic milestone in strengthening the Centre's analytical capabilities. While the cytometer enables detailed, multiparametric cell characterisation thanks to its five lasers and advanced automation, the Incucyte offers dynamic, real-time monitoring of cell cultures within their physiological environment.

Thanks to the complementarity of these technologies, we are able to combine in-depth quantitative analyses with the continuous observation of biological phenomena, paving the way for a more comprehensive understanding of cellular mechanisms.

Together, these instruments help improve the quality of the data produced and accelerate advances in biomedical research, particularly in the fields of immunology and oncology. ●

› Our supporters

At the Centre Léon Bérard, we know that the general public, associations and local companies are there for us all year round, especially by taking part in the events we organise in aid of cancer research or patient support.



› Gala dinner

On Monday, November 17, 2025, the Centre Léon Bérard held the seventh edition of its Gala Dinner at the Lyon Marriott Cité Internationale hotel. This event is something of a tradition now, and brought together 320 guests, corporate sponsors and major individual donors, all with the same goal: advancing cancer research.

The ambiance was elegant as guests enjoyed an evening marked by emotion, generosity and commitment, all for a good cause. Thanks to their efforts, the amazing sum of €431,000 was raised.

This sum is earmarked for the purchase of an Aviti24 machine, used for the multi-omic analysis of tumours - a first in France within the field of oncology. ●

› Sponsored run to fight cancer

The region's sporting calendar features two major events towards the end of the year: the Beaujolais Marathon and the SaintéLyon. But there was a difference this year, with both events selling charity running bibs.

The principle is very simple: each participant commits to raising money to support cancer research. Once the required amount is reached, the bib is validated, and the sports challenge becomes a concrete act of solidarity.

In all, nearly 300 runners supported the Centre Léon Bérard by taking part, raising almost €80,000.

The Centre Léon Bérard warmly thanks all the participants, as well as the organisers of the two races, for their faith and commitment. ●



› La Scintillante – a new record year

On Sunday, September 28, 2025, the Parc de la Tête d'Or was filled with celebrations and solidarity for the 6th edition of La Scintillante, a fixture in Lyon's calendar that combines sport, socialising and a pledge to supporting the Centre Léon Bérard.

More than 6,000 people turned up for the 5K walk or the 9K run. This edition set a new record: more than €400,000 was raised to fund research projects under way at the Centre Léon Bérard.

A new record demonstrating the generosity and collective strength of La Scintillante! We would like to thank all the participants, partners, companies and volunteers who helped make this 6th edition of La Scintillante such a success! ●



› The associations

The Centre Léon Bérard enjoyed the support of more than 300 associations in 2025. Of varying sizes and with different goals, these associations organise events like sales, concerts, and sports events to support research conducted at the Centre Léon Bérard, and programmes aimed at improving the comfort and quality of life of the patients in its care.

Their support also comes in the form of spontaneous donations, or getting involved in memory of a member who has died.

They are more and more active every year, and we wish to thank them, as well as all their volunteers, for their support and their commitment to standing alongside us. ●

› A fundraising appeal to finance work on our new haematology unit

In December 2025, the Centre Léon Bérard launched a major fundraising campaign to improve the comfort and well-being of patients hospitalised in sterile haematology rooms.

Work scheduled for 2026 will include modernising the current haematology unit. In order to do this, the care team, in consultation with patients and the facility's technical departments, began exploring ways to make these rooms more comfortable and functional.

These improvements will be made possible through donations from individuals, companies and associations that support this project.

Nearly €200,000 in donations was raised in December 2025 during the first stage of a campaign that will continue for several more months. ●

› Thank you to our donors

List of associations and foundations that supported the Centre Léon Bérard in 2025

- ADEPREV
- ADT Saint-Jacques-de-Tarentaise
- AEI de l'ECAM Lyon
- AFIPH Entreprises Isère Rhodanienne
- ALGM Gymnastique
- Amicale Boule Longearde
- Amicale Classe 1966 de Bourgoin-Jallieu
- Amicale Classes en 5 de Deux Grosnes
- Amicale Classes en 7 de Saint-Julien
- Amicale des Anciens Bouchers Charcutiers Traiteurs de Saint-Denis-lès-Bourg
- Amicale des Anciens d'Oyonnax
- Amicale des Classes en 7 de Gleizé
- Amicale des Étudiants en Pharmacie de Lyon
- Amicale des Internationaux de Villeurbanne
- Amicale des Parachutistes Beaujolais
- Amicale des Retraités CGE
- Amicale des Sapeurs-Pompiers de Toussieu
- Amicale des Sapeurs-Pompiers de Villefranche-sur-Saône
- Amicale du Personnel du LPP St Joseph
- Amicale Retraité(e)s Groupe Plattard de Villefranche-sur-Saône
- Amis de la Nature Saint-Jean-de-Niost
- Anciens des Cars Philibert
- Appel
- Aristot
- Arscenic
- AS Savigny Foot
- ASA Belley
- Assemblée des Amis de Collandre
- Association 111 des Arts
- Association ACCA Biol
- Association ACCAPL
- Association Accordéon Club de Bourgoin-Jallieu
- Association Actions CO LPP St Joseph
- Association Aikikai Club
- Association Amitié et Chansons
- Association Anim'Montbernier
- Association Arcade
- Association Beaujolais Road Runners
- Association Brillez pour Francheleins
- Association Cancer Agir Tous Ensemble
- Association Caper Nord Isère
- Association Cercle 2
- Association Classes en 2 d'Affoux
- Association Classes en 5 de Francheleins
- Association Club des Palombes
- Association CO Chandieu Cyclo
- Association Cœur Commerçant de Saint-Pierre-de-Chandieu
- Association COM en Beaujolais
- Association Comité Fleurissement de Marboz
- Association de Défense des Victimes de l'Amiante
- Association de Gestion de l'Établissement Assomption Lyon
- Association des Classes en 4 de Saint-Pierre-la-Palud
- Association des Commerçants de la Commune de Charly
- Association des Entrepreneurs Villamagnains
- Association des Familles de Saint-Didier-au-Mont-d'Or
- Association des Fins Gourmets Milottiers
- Association des Médecins et Pharmaciens du Cœur
- Association des Parents d'Élèves de l'École de Pommiers
- Association Développement Mécanique Bassin de Vie de Bourg
- Association Domani
- Association Écurie les Gones
- Association Entraide Toute Manifs
- Association Epagny Gym
- Association Eurydice
- Association Formamities
- Association Française de Vélocouche
- Association Francheleins Moto
- Association Générations OL
- Association Hommage Piano
- Association Izeaux la Belle Vie
- Association la Chapelle Country Dancers
- Association la Troupe du Coteau de Chatanay
- Association la Villa Hispanica
- Association Laïque Gerland la Mouche
- Association le Jet d'Encre de Morgane
- Association les Audacieuses
- Association les Cloch' Pieds
- Association les Frênes Verts de St-Paul-en-Jarez
- Association Locale ADMR de Pommiers
- Association Loisirs Sports et Culture d'Ozon
- Association Lou Patois Revin
- Association Maison de Pays en Bresse
- Association Media Rev Radio
- Association PER S Amusa
- Association Petits Princes
- Association Photo Club de Montmerle
- Association PLO Basket
- Association Roc' n' Rose
- Association Saint-Marc
- Association Saint-Pierre Sport Attitude
- Association Sainte-Anastasie Loisirs et Patrimoine
- Association Savoyarde des Décorés du Travail
- Association Soins et Santé
- Association Solea Tignes
- Association Sportive de Montchat

- Association Sportive du Collège la Varandaine
- Association Sportive Scolaire Cusset B
- Association Sports et Loisirs de Marges
- Association St-Marcellin Sports
- Association Standards du Soleil
- Association Syndicale Libre Lot la Buissonnière
- Association Team Jan
- Association Thiolières Bouge
- Association Timdream
- Association Tous avec Maddy et les Enfants Malades
- Association U.N.C. Alpes A.F.N. Annemasse
- Association Un Horizon d'Espoir
- Association Vaipoe Tahiti
- Association Val Deuche Saône
- Association Volodalen
- AUVR Tennis de Table
- Badminton Club Villeurbannais
- Badminton Evasion Bron
- Bella Italia de Sathonay
- Bookbouquine
- Bridge Club de Bourg
- Bron Handball
- CDSA 74
- Centre Communal Action Sociale d'Éveux
- Centre d'Arts Martiaux Pondinois
- Cercle des Supporters de Bourg-Argental
- Cercle Philosophique Universalis
- Chant d'Yeux en Chœur
- Chaponnay contre le Cancer
- Charité Bellecour chez Cuisine et Dépendance
- Chorale Chant Arnas
- Classe en 6 de Villeneuve
- Classes de Larnage
- Clima Teck
- Clothérapie Association
- Club Athéna
- Club de l'Espérance
- Club de la Gaieté de Bans
- Club de Patchwork et Art du Fil de Bellignat
- Club de Pétanque de Saint-Romain-de-Jalionas
- Club des Activités Sportives des Retraités d'Oyonnax
- Club des Sports de Chamonix
- Cobaty Haute-Savoie Léman
- Collectif Triplettes Roses
- Comité Aide Prévention Encourage
- Comité d'Action Sociale de la Forteresse
- Comité de l'Ain de la Ligue contre le cancer
- Comité de l'Allier de la Ligue contre le cancer
- Comité de l'Ardèche de la Ligue contre le cancer
- Comité de la Drôme de la Ligue contre le cancer
- Comité du Rhône de la Ligue contre le cancer
- Comité de la Savoie de la Ligue contre le cancer
- Comité des Fêtes de Massieux
- Comité des Fêtes de Toussieu
- Comité des Fêtes de Villeneuve
- Comité des Fêtes le Crestet
- Comité d'Intérêt Local Mermoz Nord Laennec Transvaal
- Comité Local d'Action Sociale de Torchefelon
- Conseil de la Vie Lycéenne du Lycée Juliette-Récamier
- COST association
- Courir Moroges
- Créart's la Récré de Vos Idées
- Des Étoiles dans la Mer
- Des Fourmis dans les Pattes
- Discodayz
- Don du Sang
- Éco-Run des Cardons
- Entente Football de Chautagne
- Entente Val d'Hyères
- Entente Vernaissonnaise des Artisans et Commerçants
- Envie d'un Sourire
- Espace Socio-Culturel du Pays de la Pierre
- Espoir Cancer
- Espoir Santé Harmonie
- Fédération ADMR de Haute-Savoie
- Fédération BTP74
- Fédération Française de Basket-Ball
- Fée Danse C
- Fondation ARC
- Fondation pour la Recherche Médicale
- Football Club Bourguisan
- Football Club de Saint-Maurice-de-Gourdans
- Foyer de Vie Claude Bernard
- Fraternité de Saint-Maurice d'Ardèche
- Give Hope Association
- Groupe Folklorique du Pays de Bresse
- Groupe Scolaire Chevreuil Lestonnac
- Groupement des Commerçants Artisans et Libéraux Chaleysinois
- Groupement des Œnologues Beaujolais
- GSL Ski Loisir
- Guéguen Cuvillier
- Gym Chassieu
- Gym Volontaire de Lagnieu
- Gymnastique Volontaire de Baudrières
- Habitat et Humanisme Soin
- Hauterives Animation
- Heyrieux Croise les Fuseaux
- Horizons
- Influences
- Interclasse en 3 d'Arnas
- Interclasse en 4 de Montmerle
- Kop Virage Nord
- L'Asso des Perrières
- La Gaieté Laurentinoise
- La Randomarinoise
- Le Bistrot de Tatina
- Le Bonheur Échetois
- Le Cercle des Amis de Vitruve
- Le Grenier Solidaire Valsenhône
- Les Amis de Coligny
- Les Amis de Michelle et René
- Les Amis du Carrefour d'Amitié
- Les Amis du Jumelage
- Les Ateliers Créatifs de Saint-Jean
- Les Cent Mémoires
- Les Chœurs de Villeurbanne Vox Urbana
- Les Copains des 7 de Chuzelles
- Les Enfants de la Joyeuse
- Les Folklores du Haut Bugey
- Les Jardiniers du Dimanche
- Les Passagers de l'Histoire
- Les Randonneurs de Milotte
- Ligue de Golf de Lyon
- Ligue des Fadas du Hand Étudiant
- Ligue Fédération Française de Karaté
- Ligue Nationale contre le Cancer
- Lions Club Annonay
- Lions Club Brou Bourg-en-Bresse
- Lions Club de Roanne
- Lions Club Lyon Avenir
- Lions Club Lyon Bellecour et Sud
- Lions Club Monts Beaujolais
- Lions Club Pérouges
- Lions Club Villages Beaujolais
- Lycée Belmont de Lyon
- Maxi Aide Grand Lyon
- MJC du Vuache
- MSD Avenir
- Musique à Vivre
- OGEC aux Lazaristes la Salle Lyon
- Pact en Fête
- Passe le Cap
- Perrin et Gruel
- Plus Cérébrale que Nous Tumeur
- Pour le Plaisir
- Rencontre et Découverte
- Restons Jeunes
- Retrolocomotion du Bion
- Rêve Mille Étoiles
- Ros'en-Vie
- Rotary Bourg-en-Bresse Brou
- Rotary Club d'Annonay
- Rotary Club Porte de l'Ain
- Rouler pour la Vie by Cécile
- Rugby Club de Chasse-sur-Rhône
- Rugby Club de la Sévenne
- Run In Pont-de-Vaux
- SAS Millénium Patrimoine
- Savoie en Yoga et Relaxation
- Scrabble Club de Lyon
- Seconde Vie la Vie Durable Commence Ici
- Sérézin d'Hier
- Seynod Yoga Club
- SFCE
- Société Beaujolaise d'Odonto-Stomatologie
- Société de Chasse de Montceaux
- Société des Amis de l'Instruction
- Société Nautique de Sauvetage Saint-Fons
- Sœurs St Joseph
- Soleil Automne
- Solidarité Sourires d'Enfants
- Sou des Écoles de Saint-Pierre-la-Palud
- Syndicale Libre des Propriétaires du Domaine de la Croix
- Ta Vitae
- Tellement Proches
- Tennis Club Andancettois
- Tennis Club Belmont
- Tennis Club de Mions
- Tennis Club Froberville
- Tous Unis sur le Green
- Tout Faire pour un Sourire d'Enfant
- UCDR Rhône-Alpes
- Un Rêve à Moto
- Union Laïque de Miribel
- Ventoux contre Cancer



» Table showing the use of resources

Annual account of how resources raised from the public were used

This table has been certified by our auditors Advolis Orfis. The Statement of Income and Expenditure by Source and Use (CROD) is available from the Donor Relations team to anyone who wishes to see it.

2025	
USE OF FUNDS BY DESTINATION (in euros)	OF WHICH DONATIONS FROM THE PUBLIC
USE OF FUNDS DURING FINANCIAL YEAR	
1. Social programs	6,769,930
1.1 Carried out in France	6,769,930
Actions carried out by the institution	6,769,930
• Fundamental/translational/clinical research	6,418,640
• Patient care & quality of life	351,291
Payments to a central institution or to other institutions operating in France	-
1.2 Carried out abroad	-
Actions carried out by the institution	-
Payments to a central body or to other bodies operating abroad	-
2. Fundraising expenses	749,367
2.1 Costs of appeals for donations from the public	749,367
2.2 Search costs for other resources	-
3. Operating expenses	488,624
TOTAL USE OF FUNDS	8,007,921
4. Allocation to provisions and depreciation	-
5. Dedicated funds carried forward for the year	-
Surplus from donations from the public in the financial year	7,217,366
TOTAL	15,225,287

2025	
RESOURCES BY ORIGIN (in euros)	TOTAL
RESOURCES IN THE FINANCIAL YEAR	
1. Resources linked to donations from the public	15,225,287
1.1 Contributions without consideration	-
1.2 Donations, legacies and sponsorships	15,225,287
• Manual donations	9,191,950
• Bequests, donations and life insurance	6,033,337
1.3 Other resources linked to donations from the public	-
TOTAL RESOURCES	15,225,287
2. Reversal of provisions and depreciation	-
3. Use of previous dedicated funds	
Deficit from donations from the public in the financial year	
TOTAL	-
Deferred resources linked to donations from the public at the start of the financial year (excluding dedicated funds)	46,375,598.14
(+) Surplus or (-) shortfall of donations from the public	7,217,366
Net (-) investments and (+) divestments linked to donations from the public in the financial year	-6,404,486
Deferred resources linked to donations from the public at the end of the financial year (excluding dedicated funds) (*)	47,188,478



CONCEPTION

Alteriade

ILLUSTRATIONS

Centre Léon Bérard

PHOTOGRAPHIC CREDITS

Romane Tourral - Morgan Bove - Romain Etienne -
peopleimages.com, Davide Angelini / Adobe Stock -
Visuels et Photos, Service communication
du Centre Léon Bérard





CENTRE
DE LUTTE
CONTRE LE CANCER

LEON
BERARD



WWW.CENTRELEONBERARD.FR